Changes in Alcohol Use Among Adults with Cancer Participating in the ECOG-ACRIN EAQ171CD Tobacco Treatment Trial

Abstract Background: Alcohol and tobacco use are known carcinogens. Treating alcohol and tobacco co-use can improve treatment and survivorship outcomes among patients diagnosed with cancer. Methods: We conducted a post hoc analysis of ECOG-ACRIN EAQ171CD trial participants within the NCI Community Oncology Research Program (NCORP), examining changes in alcohol use among adults receiving the virtual sustained treatment (VST) for tobacco use intervention versus enhanced usual care (EUC; Quitline referral). Multivariable logistic regression assessed changes in alcohol use disorder risk at 3 and 6 months using the AUDIT-C. Results: At baseline, participants (N = 305) were classified as no risk (31%), low/minimal risk (38%), moderate risk (23%), or high risk (8%) for alcohol use disorder. The mean age was 55.6 years, participants smoked for an average of 33 years, and 18% had alcohol-associated tumors. Participants randomized to EUC were more likely to shift to a lower alcohol risk category than those in the VST arm at 3 months (39% vs 27%) and 6 months (33% vs 27%). There was no significant difference in the odds of shifting to a lower risk category for VST vs EUC at 3 months (adjusted OR = 0.56, 95% CI 0.26–1.18, p = 0.125) or at 6 months (adjusted OR = 0.57, 95% CI 0.25–1.28, p = 0.172). Conclusions: Patients diagnosed with cancer and engaging in alcohol and tobacco co-use can achieve reductions in alcohol use and risk. Impact: Integrating tailored, co-use–focused strategies into cessation programs may improve changes in modifiable risk behaviors.

Authors

Institutions

Publication Details

Journal
Cancer Epidemiology Biomarkers & Prevention
Published
2026-09-09
DOI
https://doi.org/10.1158/1055-9965.epi-26-0589
Primary Topic
Alcohol Consumption and Health Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Changes in Alcohol Use Among Adults with Cancer Participating in the ECOG-ACRIN EAQ171CD Tobacco Treatment Trial

Douglas E. Levy, Lucy Finkelstein‐Fox, Alona Muzikansky, Sai Priyanka Mellacheruvu et al.
Cancer Epidemiology Biomarkers & Prevention
Alcohol Consumption and Health Effects
article

Changes in Alcohol Use Among Adults with Cancer Participating in the ECOG-ACRIN EAQ171CD Tobacco Treatment Trial

Douglas E. Levy, Lucy Finkelstein‐Fox, Alona Muzikansky, Sai Priyanka Mellacheruvu, Alyssa Throckmorton, Autumn W. Rasmussen, Jamie S. Ostroff, JoRean D. Sicks, Molly M. Greenwade, Michael A. Thompson, Angela Wangari Walter, Brett Goshe, Ruth C. Carlos, Rachel Rosen, Martha S. Tingen, Nathan D. Munson, Elyse Richelle Park, Irina Gonzalez, Lynne I. Wagner, B. Herman, Bharat Jenigiri, Susan Regan, David M. King, Ilana F. Gareen, Alex Taurone, Brian L. Burnette, Laura Malloy
article en

Abstract

Abstract Background: Alcohol and tobacco use are known carcinogens. Treating alcohol and tobacco co-use can improve treatment and survivorship outcomes among patients diagnosed with cancer. Methods: We conducted a post hoc analysis of ECOG-ACRIN EAQ171CD trial participants within the NCI Community Oncology Research Program (NCORP), examining changes in alcohol use among adults receiving the virtual sustained treatment (VST) for tobacco use intervention versus enhanced usual care (EUC; Quitline referral). Multivariable logistic regression assessed changes in alcohol use disorder risk at 3 and 6 months using the AUDIT-C. Results: At baseline, participants (N = 305) were classified as no risk (31%), low/minimal risk (38%), moderate risk (23%), or high risk (8%) for alcohol use disorder. The mean age was 55.6 years, participants smoked for an average of 33 years, and 18% had alcohol-associated tumors. Participants randomized to EUC were more likely to shift to a lower alcohol risk category than those in the VST arm at 3 months (39% vs 27%) and 6 months (33% vs 27%). There was no significant difference in the odds of shifting to a lower risk category for VST vs EUC at 3 months (adjusted OR = 0.56, 95% CI 0.26–1.18, p = 0.125) or at 6 months (adjusted OR = 0.57, 95% CI 0.25–1.28, p = 0.172). Conclusions: Patients diagnosed with cancer and engaging in alcohol and tobacco co-use can achieve reductions in alcohol use and risk. Impact: Integrating tailored, co-use–focused strategies into cessation programs may improve changes in modifiable risk behaviors.

Cancer Epidemiology Biomarkers & Prevention
University of North Carolina at Chapel Hill (US), Aurora Health Care (US), Memorial Sloan Kettering Cancer Center (US), University of Massachusetts Lowell (US), Brown University (US), St Vincent Hospital (US), Augusta University Health (US), Massachusetts General Hospital (US), Nazareth Hospital (US), St. Vincent Hospital (US), ThedaCare (US), Baptist Memorial Health Care (US), Metro-Minnesota Community Oncology Research Consortium (US), Physicians' Clinic of Iowa (US), St. Vincent Hospital (US), CoxHealth (US), Columbia University (US)
Good health and well-being
Openalex Percentile: Top 11%
Alcohol Consumption and Health Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.